Annual net sale milestones in the Territory per license agreement.

No definition available.

Name:	txmd_AnnualNetSalesMilestones
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The reduction in royalty rate of initial rate six-months after the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S.

+ References

No definition available.

+ Details

Name:	txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent
Namespace Prefix:	txmd_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The reduction in royalty rate of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S.

+ References

No definition available.

+ Details

Name:	txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent
Namespace Prefix:	txmd_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of cash due as an upfront fee per signed agreement.

+ References

No definition available.

+ Details

Name:	txmd_CashUpfrontPaymentDue
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

THe amount of intangibles written off.

+ References

No definition available.

+ Details

Name:	txmd_IntangibleWrittenOfff
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of milestone payments payable after release of first commercial batch.

+ References

No definition available.

+ Details

Name:	txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of milestone payments payable upon FDA approval.

+ References

No definition available.

+ Details

Name:	txmd_MilestonePaymentsUponFDAApproval
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The net sales amount as defined in license agreement for step-based royalty payments.

+ References

No definition available.

+ Details

Name:	txmd_NetSalesAmountPerStepbasedRoyalty
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Number of issued patents.

+ References

No definition available.

+ Details

Name:	txmd_NumberOfIssuedPatents
Namespace Prefix:	txmd_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

No definition available.

+ Details

Name:	txmd_ProceedsFromIssuanceOfCommonStock1
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of regulatory milestone payments based on regulatory approvals for each of BIJUVA and IMVEXXY in certain specified markets.

+ References

No definition available.

+ Details

Name:	txmd_RegulatoryMilestonePaymentDue
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The percent of the net sales to be paid as royalty per license agreement.

+ References

No definition available.

+ Details

Name:	txmd_RoyaltyPercent
Namespace Prefix:	txmd_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of sales milestone payments to be paid in escalating tranches based on Theramex first attaining certain aggregate annual net sales milestones in the Territory.

+ References

No definition available.

+ Details

Name:	txmd_SalesMilestonePayments
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

+ Details

Name:	us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_FiniteLivedIntangibleAssetsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275

+ Details

Name:	us-gaap_FinitelivedIntangibleAssetsAcquired1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockPricePerShare
Namespace Prefix:	us-gaap_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents5Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents3Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents1Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents6Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents4Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents7Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents2Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents8Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents11Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents9Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents10Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents16Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=txmd_SubscriptionAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=txmd_KnightTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreement1Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=txmd_AnnoveraMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	txmd_RoyaltyTierAxis=txmd_StepBasedRoyaltyPaymentOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	txmd_RoyaltyTierAxis=txmd_StepBasedRoyaltyPaymentThreeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	txmd_RoyaltyTierAxis=txmd_StepBasedRoyaltyPaymentTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

INTANGIBLE ASSETS (Details Narrative) $ / shares in Units, € in Millions			3 Months Ended			6 Months Ended
	Aug. 06, 2018 USD ($) $ / shares shares	Jul. 30, 2018 USD ($)	Jun. 30, 2019 USD ($)	Mar. 31, 2019 USD ($)	Jun. 30, 2018 USD ($)	Jun. 30, 2019 USD ($)	Jun. 30, 2018 USD ($)	Jun. 30, 2019 EUR (€)	Jun. 30, 2019 USD ($)
Finite-Lived Intangible Assets [Line Items]
Intangible written offf						$ 78,864
Sales milestone payments \| €								€ 27.5
Regulatory milestone payment due \| €								2.0
Cash upfront payment due \| €								€ 14.0
Amortization expense			$ 48,503		$ 24,826	$ 88,948	$ 46,023
Approved Hormone Therapy Drug Candidate Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life						20 years
Domestic U.S. Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Number of issued patents								26	26
Foreign Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Number of issued patents								27	27
Domestic Utility Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Number of issued patents								12	12
Foreign Utility Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Number of issued patents								5	5
Domestic Patents - TX-004HR [Member]
Finite-Lived Intangible Assets [Line Items]
Number of issued patents								5	5
Foreign Patents - TX-004HR [Member]
Finite-Lived Intangible Assets [Line Items]
Number of issued patents								13	13
Domestic Utility Patent - Transdermal Patch Candidates [Member]
Finite-Lived Intangible Assets [Line Items]
Number of issued patents								1	1
Foreign Utility Patent - Transdermal Patch Candidates [Member]
Finite-Lived Intangible Assets [Line Items]
Number of issued patents								5	5
Domestic Utilty Patent - Opera Software [Member]
Finite-Lived Intangible Assets [Line Items]
Number of issued patents								1	1
Domestic Utility Patents Topical - Cream Candidates [Member]
Finite-Lived Intangible Assets [Line Items]
Number of issued patents								1	1
Domestic Patents - TX-009HR [Member]
Finite-Lived Intangible Assets [Line Items]
Number of issued patents								2	2
Foreign Patents Progesterone - Only Candidate [Member]
Finite-Lived Intangible Assets [Line Items]
Number of issued patents								4	4
Domestic utility patent D-limonene [Member] [Default Label]
Finite-Lived Intangible Assets [Line Items]
Number of issued patents								1	1
Subscription Agreement [Member] \| Knight Therapeutics Inc. [Member]
Finite-Lived Intangible Assets [Line Items]
Issue of common stock shares (in shares) \| shares	3,921,568
Gross proceeds	$ 20,000,000
Common stock sale price (in dollars per share) \| $ / shares	$ 5.10
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Annual net sales milestones \| €								€ 25.0
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Annual net sales milestones \| €								€ 100.0
Council License Agreement [Member]
Finite-Lived Intangible Assets [Line Items]
Payment of milestone recorded as finite-lived intangible asset		$ 20,000,000,000
Council License Agreement [Member] \| ANNOVERA [Member]
Finite-Lived Intangible Assets [Line Items]
Milestone payments upon FDA approval									$ 20,000,000
Milestone payments (payment after release of first commercial batch)									$ 20,000,000,000
Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent				50.00%
Annual royalty rate reduction of initial rate after the six-month period from commercial sale of a generic equivalent				20.00%
Step-based Royalty Payment One [Member] \| Council License Agreement [Member] \| ANNOVERA [Member]
Finite-Lived Intangible Assets [Line Items]
Royalty (percent)								5.00%	5.00%
Step-based Royalty Payment One [Member] \| Council License Agreement [Member] \| ANNOVERA [Member] \| Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Net sales amount per step-based royalty						$ 50,000,000
Step-based Royalty Payment Three [Member] \| Council License Agreement [Member] \| ANNOVERA [Member]
Finite-Lived Intangible Assets [Line Items]
Royalty (percent)								15.00%	15.00%
Step-based Royalty Payment Three [Member] \| Council License Agreement [Member] \| ANNOVERA [Member] \| Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Net sales amount per step-based royalty				$ 150,000,000
Step-based Royalty Payment Two [Member] \| Council License Agreement [Member] \| ANNOVERA [Member]
Finite-Lived Intangible Assets [Line Items]
Royalty (percent)				10.00%
Step-based Royalty Payment Two [Member] \| Council License Agreement [Member] \| ANNOVERA [Member] \| Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Net sales amount per step-based royalty						$ 50,000,000
Step-based Royalty Payment Two [Member] \| Council License Agreement [Member] \| ANNOVERA [Member] \| Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Net sales amount per step-based royalty				$ 150,000,000